Torley Helen 4

What Happened
Helen Torley, President & CEO and a director of Halozyme Therapeutics (HALO), exercised 50,000 stock options (20,000 on 6/1, 20,000 on 6/2, 10,000 on 6/3) at an exercise price of $12.07 per share (exercise cost ≈ $603,500). She sold the 50,000 resulting shares in open-market transactions across June 1–3, 2026 for total gross proceeds of approximately $3,370,008 (weighted average sale price ≈ $67.40). Net proceeds after exercise costs were roughly $2.77M. The exercises and sales were reported on a Form 4 filed June 3, 2026.

Key Details

• Transaction types: M = option exercise; S = open-market sale. The filing also shows corresponding derivative disposition lines reflecting conversion of options to shares.
• Exercise price: $12.07 per share; total exercised: 50,000 shares; total exercise cost ≈ $603,500.
• Sales: 50,000 shares sold across 6/1–6/3; gross proceeds ≈ $3,370,008; weighted avg sale price ≈ $67.40/share.
• Dates: June 1, 2026; June 2, 2026; June 3, 2026. Form 4 filed June 3, 2026.
• Footnotes: F1 — sales were made pursuant to a written 10b5-1 trading plan adopted March 21, 2025; sales represent shares acquired upon exercise of ten-year options (expiring Feb 2027). F11 — the options were originally granted Feb 22, 2017. Footnotes F2–F10 detail the price ranges for grouped sales and can be requested for per-price breakdowns.
• Shares owned after the transactions: not specified in the provided filing details.

Context
These transactions reflect an exercise of long-dated options followed by an immediate sale of the acquired shares under a pre-established 10b5-1 plan (effectively a cashless exercise + sell). Such transactions are commonly used by insiders for liquidity and tax management and are not, by themselves, proof of a change in view on the company’s prospects.